Ocuphire Pharma, Inc. (OCUP)
| Market Cap | 56.35M |
| Revenue (ttm) | -1.15M |
| Net Income (ttm) | -70.50M |
| Shares Out | 18.85M |
| EPS (ttm) | -5.62 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 180,299 |
| Open | 2.78 |
| Previous Close | 2.84 |
| Day's Range | 2.71 - 3.04 |
| 52-Week Range | 2.59 - 13.81 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 23.50 (+686.0%) |
| Earnings Date | n/a |
About OCUP
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances, and pharmacologically induced mydriasis, as well as that is in Phase II clinical trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to tar...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for OCUP stock is "Strong Buy." The 12-month stock price forecast is 23.50, which is an increase of 685.95% from the latest price.
News
Ocuphire to Host Virtual Investor R&D Day on January 31st
Update on Late-Stage Clinical Trials in the APX3330 and Nyxol Programs as well as Commercial Insights for Nyxol for RM and Presbyopia by Six Leading KOLs
Ocuphire Provides Corporate Update: Announcing Enrollment Completion of Phase 3 Nyxol Trial, Enrollment Initiation of...
Completed Enrollment of Nyxol ® LYNX-1 Phase 3 NVD Trial
Ocuphire Expands Prestigious Medical Advisory Board with Six New KOLs to Support Advancement of Late-Stage Ophthalmic...
FARMINGTON HILLS, Mich, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies ...
Ocuphire Announces Enrollment of First Patients in Second Phase 3 Pivotal Trial (MIRA-3) for Nyxol® in Reversal of My...
RM Indication Allows for Rapid Recruitment with Top-line Results Expected in Early 2022
Ocuphire Pharma, Inc. (OCUP) Loses 17.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Ocuphire Pharma, Inc. (OCUP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts i...
Ocuphire Invited to Present Clinical Data on Nyxol® and APX3330 at the American Academy of Ophthalmology 2021 Annual ...
FDA Approves First Pharmaceutical Therapy to Treat Presbyopia; Nyxol on Track to Start Phase 3 Presbyopia Trials in First Half of 2022
Ocuphire Announces Publications Featuring the Ref-1 Protein, a Transcription Factor Regulator, as a Novel Therapeutic...
New Review Publications Underscore the Role of the APE1/Ref-1 Protein in Multiple Pro-angiogenic Pathways Associated with Neovascular Eye Disease Including Diabetic Retinal Diseases and Age-Related Macu...
Ocuphire's Clinical Phase 2b Oral Drug Candidate APX3330 for Retina to be Featured at the OIS Retina@ASRS and ASRS 20...
FARMINGTON HILLS, Mich., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies...
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FARMINGTON HILLS, Mich., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed entirely of...
Ocuphire Pharma Presenting at Four Conferences in September
Euro Forums 2021 Virtual Retina Forum on September 8, 2021
Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update
Continued Momentum in Nyxol ® Programs with Announcement of Positive Top-Line Results from VEGA-1 Phase 2 Trial in Presbyopia
Ocuphire Pharma Presenting at Two Conferences in August
Canaccord Genuity 41 st Annual Growth Conference being held virtually on August 10-12, 2021
Ocuphire Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Pha...
Highlights Favorable Safety Profile of the Oral New Chemical Entity APX3330 and Its Novel Anti-Angiogenic and Anti-Inflammatory Mechanism of Action Properties Relevant to a Broad Range of Retinal Diseases
Ocuphire Selected to Present at Multiple Ophthalmic Conferences in July
Positive Results from Phase 2 Presbyopia (VEGA-1) and Phase 3 Reversal of Mydriasis (MIRA-2) Studies to be Presented at 2021 ASCRS Annual Meeting in Las Vegas
Ocuphire Pharma Stock Surges After Nyxol Combo Treatment Meets Study Endpoints In Presbyopic Patients
Ocuphire Pharma Inc (NASDAQ: OCUP) announced data from the VEGA-1 Phase 2 trial evaluating the efficacy and safety of Nyxol in combination with low-dose pilocarpine (LDP) in presbyopic subjects. Presby...
Ocuphire's VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpoints
Met primary endpoint with statistical significance at 1 hour with 61% of subjects treated with Nyxol ® plus low-dose pilocarpine (LDP) gaining ≥ 15 letters (3 lines) in near vision
Processa Pharmaceuticals In-Licenses Ocuphire's Anticancer Agent
Processa Pharmaceuticals Inc (NASDAQ: PCSA) has entered into a licensing agreement with Ocuphire Pharma Inc (NASDAQ: OCUP) to in-license RX-3117. RX-3117 is an oral anticancer agent with an improved pha...
Ocuphire Announces Addition to the Russell Microcap® Index
FARMINGTON HILLS, Mich., June 11, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on development and commercialization of the...
Ocuphire Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market
Capital Raise Expected to Extend Runway Through Late 2022 and Allow Additional Milestones for a Potential NDA Filing for Nyxol in Reversal of Mydriasis Capital Raise Expected to Extend Runway Through La...
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
FARMINGTON HILLS, Mich., June 04, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies...
Ocuphire to Host Key Opinion Leader Event on Nyxol® as a Potential New Treatment Option for Reversing Pharmacological...
Highlights of Recent Positive Data from Nyxol's Phase 3 Registration Trial
Ocuphire Granted Two New U.S. Patents Covering Late-Stage Drug Candidate Nyxol®, Including for the Treatment of Presb...
Newly Issued Claims Extend Patent Protection to Year 2039 for Nyxol ® Combination Therapy for Presbyopia
Ocuphire Announces Financial Results for the First Quarter 2021 and Provides Corporate Update
Reported Positive Data in First Pivotal Phase 3 Trial for Nyxol Eye Drops with Plans to Advance Towards NDA Submission and Commercialization in Reversal of Mydriasis Indication
Ocuphire's APX3330 for Retinal Diseases to be Presented at the 2021 Association for Research in Vision and Ophthalmol...
Oral Administration of APX3330 Reduced Neovascularization in a Pre-Clinical Mouse Model of Laser-Induced Choroidal Neovascularization
Ocuphire Pharma Starts Mid-Stage APX3330 Study In Diabetic Retinopathy Patients
Ocuphire Pharma Inc (NASDAQ: OCUP) has screened the first patient in Phase 2 ZETA-1 trial evaluating APX3330 in non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy ...